Request an Appointment

Resetting your body, restarting your life

Resetting your body, restarting your life

Bone marrow transplantation is among the greatest success stories in cancer care. It has boosted cure rates for some blood cancers from nearly zero to 90 percent. The Fred Hutch Bone Marrow Transplant Program at SCCA has led since the beginning, when Nobel Prize-winner E. Donnall Thomas, MD, and his team first developed clinical use of transplants at Fred Hutch in the 1970s. Today, our doctors and researchers continue to innovate, making this life-saving treatment more effective and more widely available than ever.

Important new developments are showing the way to a further improvement in results so that many more patients with otherwise incurable diseases will have a reasonable chance of long survival and cure

E. Donnall Thomas, MD1990 Nobel Laureate

What is a bone marrow transplant?

After you have chemotherapy, radiation therapy or both to destroy the cells causing your disease, a blood or marrow transplant restarts your body’s ability to make healthy new blood cells. The transplanted cells, called hematopoietic (blood-forming) stem cells, can come from bone marrow, circulating blood or umbilical cord blood donated by a new mother. Stem cells offer the possibility of a “reset” for diseases like leukemiaHodgkin lymphomanon-Hodgkin lymphoma, multiple myeloma and myelodysplastic syndrome.

What is my transplant path at SCCA?

You’ll begin with an initial consultation, where you meet SCCA transplant experts who answer your questions and help you plan and prepare yourself and your family. Next comes finding and preparing a stem cell donor, if you need one, or preparing to have your own stem cells collected for use in your transplant later. We guide you, step by step, as you get ready.

When you arrive at SCCA for your actual transplant, your experienced team thoroughly evaluates your health before providing your conditioning treatment (chemotherapy, radiation or both) and infusing the donor stem cells. As your bone marrow and immune system recover, we carefully monitor you and support you and your personal caregiver until you’re ready to return to your referring doctor’s care.

The experience to defy limitations

Our goal is to get patients back home, to have patients living the life they want to lead outside of their cancer, and we need to do that in partnership with our referring providers and we take that charge very seriously.

Damian J. Green, MD Hematologist Oncologist, Seattle Cancer Care Alliance

Doctors at the Fred Hutch Bone Marrow Transplant Program at SCCA have performed more than 15,000 bone marrow transplants, more than any other institution in the world. Our deep experience — in caring for patients and families and leading groundbreaking scientific research — allows us to look beyond today’s boundaries to develop the advanced transplant regimens of tomorrow.

We’ve pioneered innovations like less toxic, reduced-intensity (non-myeloablative) transplants for older people or those with multiple health problems and minimally mismatched, haploidentical or cord blood transplants, which mean nearly everyone who needs a donor can find one.


My whole family would agree that our whole experience here from Day 1 was and still is one of the most defining things in our lives. These are the best kind of people who you never want to see. When we came here, there was clearly a different mentality

Ted Ave’LallemantAcute lymphocytic leukemia patient

Do more than survive: thrive

With our commitment to caring and excellence, SCCA constantly works to improve transplant survival rates and also ensure our patients thrive.  

Ours is one of only 5 out of 177 transplant centers nationwide whose patients achieved higher-than-expected survival rates for at least six years in a row. Advances made here to reduce post-transplant complications, like graft-versus-host disease, have led to better long-term survival. Our Long-Term Follow-up Program, providing lifelong support for transplant recipients, is unmatched in the world.